Tdap Vaccination in Patients with a History of Guillain-Barré Syndrome

Introduction to Guideline Framework

• The Advisory Committee on Immunization Practices (ACIP) distinguishes between contraindications and precautions for Tdap administration, with GBS occurring <6 weeks after a previous tetanus toxoid-containing vaccine listed as a precaution, not a contraindication, and recommends careful evaluation of risks and benefits 1, 3, 4
• If the benefit of vaccination is believed to outweigh the risk, the vaccine should be administered, with Tdap preferred over Td if otherwise indicated 1, 2, 6, 5

Clinical Decision Algorithm

• The Centers for Disease Control and Prevention (CDC) recommends determining the temporal relationship between the prior GBS episode and tetanus toxoid-containing vaccine, with vaccination proceeding as indicated if no temporal association exists 1, 2, 3
• If GBS occurred within 6 weeks of a tetanus toxoid-containing vaccine, a risk-benefit assessment is necessary, considering factors such as protection against tetanus, diphtheria, and pertussis, as well as wound management and pregnancy-related protection 1, 7

Important Clinical Considerations

• The American Academy of Pediatrics (AAP) notes that real-world data support vaccination safety in GBS patients, with a low recurrence risk and high disease prevention benefit 2, 6, 5
• The ACIP recommends that clinicians distinguish between Td and Tdap, with the precaution specifically relating to the tetanus toxoid component, not pertussis, and pertussis components not contraindicated for stable neurologic conditions, including resolved GBS 1, 3, 7, 6, 5
• For wound management and pregnancy, careful consideration of the risk-benefit assessment is necessary, with Tdap recommended during each pregnancy to protect the infant 7, 1